PE20030340A1 - Metodo para el tratamiento o prevencion de desgaste oseo - Google Patents
Metodo para el tratamiento o prevencion de desgaste oseoInfo
- Publication number
- PE20030340A1 PE20030340A1 PE2002000815A PE2002000815A PE20030340A1 PE 20030340 A1 PE20030340 A1 PE 20030340A1 PE 2002000815 A PE2002000815 A PE 2002000815A PE 2002000815 A PE2002000815 A PE 2002000815A PE 20030340 A1 PE20030340 A1 PE 20030340A1
- Authority
- PE
- Peru
- Prior art keywords
- antihuman
- treatment
- antihumanetic
- hfe7a
- antibody
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 2
- NMARPFMJVCXSAV-UHFFFAOYSA-N 5-[(3,5-diethoxy-4-pyrrol-1-ylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C=1C(OCC)=C(N2C=CC=C2)C(OCC)=CC=1CC1=CN=C(N)N=C1N NMARPFMJVCXSAV-UHFFFAOYSA-N 0.000 abstract 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 abstract 1
- 229950006700 edatrexate Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229950011561 epiroprim Drugs 0.000 abstract 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 abstract 1
- 229960005293 etodolac Drugs 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960001929 meloxicam Drugs 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 229960002702 piroxicam Drugs 0.000 abstract 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229960000371 rofecoxib Drugs 0.000 abstract 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION PARA EL TRATAMIENTO DE DESGASTE OSEO OCASIONADO POR UNA ENFERMEDAD QUE ACTIVA OSTEOCLASTOS COMO ARTRITIS REUMATOIDE QUE COMPRENDE UN VEHICULO O DILUYENTE, ANTICUERPO MONOCLONAL Fas ANTIHUMANO HFE7A, UN ANTICUERPO MONOCLONAL Fas ANTIHUMANO HFE7A HUMANIZADO, ANTIINFLAMATORIOS NO ESTEROIDEOS (DICLOFENACO, LOXOPROFEN, CELECOXIB, ETODOLAC, MELOXICAM, ROFECOXIB, PIROXICAM, ENTRE OTROS); ANTIRREUMATICOS, INTERFERON GAMMA, COMPUESTOS CON ACTIVIDAD ANTAGONISTA A FOLATO, ANTAGONISTA A DIHIDROFOLATO COMO METOTREXATO, EDATREXATO, EPIROPRIM, IOMETREXOL, ENTRE OTROS. TAMBIEN SE REFIERE A FAS ANTIHUMANO ELABORADO MEDIANTE TECNOLOGIA RECOMBINANTE A PARTIR DE UNA CADENA LIGERA HUMANIZADA Y UNA CADENA PESADA OBTENIDA DE PLASMIDO RECOMBINANTES PORTADOS POR CEPAS TRANSFORMADAS DE E COLI
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001257436 | 2001-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030340A1 true PE20030340A1 (es) | 2003-04-05 |
Family
ID=19085098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000815A PE20030340A1 (es) | 2001-08-28 | 2002-08-26 | Metodo para el tratamiento o prevencion de desgaste oseo |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1421118A1 (es) |
| AR (1) | AR036305A1 (es) |
| CA (1) | CA2458993A1 (es) |
| PA (1) | PA8553901A1 (es) |
| PE (1) | PE20030340A1 (es) |
| WO (1) | WO2003020768A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003242265A1 (en) * | 2002-06-07 | 2003-12-22 | Sankyo Company, Limited | Combined effects of therapeutic or preventive agent composition for bone breakage |
| US20050032807A1 (en) * | 2003-08-06 | 2005-02-10 | Rosenwald Lindsay A. | Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives |
| BRPI0917554A2 (pt) * | 2008-08-01 | 2017-06-20 | Axis Inc | agente de tratamento ou agente de prevenção para oesteoartrite |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ515598A (en) * | 1999-05-24 | 2004-05-28 | Sankyo Co | Synergistic medicinal compositions containing anti-Fas antibody and a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity |
-
2002
- 2002-08-26 PE PE2002000815A patent/PE20030340A1/es not_active Application Discontinuation
- 2002-08-27 WO PCT/JP2002/008630 patent/WO2003020768A1/en not_active Ceased
- 2002-08-27 EP EP02762875A patent/EP1421118A1/en not_active Withdrawn
- 2002-08-27 AR ARP020103216A patent/AR036305A1/es not_active Application Discontinuation
- 2002-08-27 CA CA002458993A patent/CA2458993A1/en not_active Abandoned
- 2002-08-28 PA PA20028553901A patent/PA8553901A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8553901A1 (es) | 2003-06-30 |
| EP1421118A1 (en) | 2004-05-26 |
| CA2458993A1 (en) | 2003-03-13 |
| AR036305A1 (es) | 2004-08-25 |
| WO2003020768A1 (en) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| EA200500488A1 (ru) | Фармацевтические составы модафинила | |
| CR9975A (es) | Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina | |
| NO20044038L (no) | Glutaminylbaserte DRIV-inhibitorer | |
| MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| CO6220978A2 (es) | Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos | |
| BRPI0506679A (pt) | métodos de tratar osteoartrite com antagonistas de il-6 | |
| AR041374A1 (es) | Derivados de 2-oxodihidropiridina n- sustituidos | |
| EA200401160A1 (ru) | Производные тиазола и оксазола, которые модулируют активность ppar | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| NO20030896L (no) | Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| MX377605B (es) | Inmunoglobulina híbrida conteniendo un enlace no-peptidílico. | |
| CL2004000868A1 (es) | Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis. | |
| ATE485300T1 (de) | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine | |
| TW200741134A (en) | Optical device for creating an illumination window | |
| PH12021550244A1 (en) | Anti-btla antibody | |
| CR20210375A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| MY165625A (en) | Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis | |
| ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| PE20030340A1 (es) | Metodo para el tratamiento o prevencion de desgaste oseo | |
| MX2021014773A (es) | Formas de sales cristalinas de un inhibidor de cinasas. | |
| PE20091880A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| DK1166788T3 (da) | Lægemidler til ledsygdomme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |